Highlights From ATS 2013: An Update on Advances in COPD

Slides:



Advertisements
Similar presentations
Bronchodilation is the cornerstone of treatment Pharmacological treatment of COPD.
Advertisements

Component 4 Medications. Key Points - Medications  2 general classes: – Long-term control medications – Quick-Relief medications  Controller medications:
Lancet Respir Med 2013; 1: 199–209 R4.신재령 / Prof. 박명재
LSU Journal Club Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPD WISDOM study H. Magnussen MD, et al. Nisha Loganantharaj, PGY1 April 21,
GOLD 2017 major revision: Summary of key changes
Thank you for viewing this presentation.
Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol–fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE):
COPD Management.
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Harrison CN et al. Proc ASH 2015;Abstract 59.
Overview The Burden of COPD Main Challenges in the Diagnosis of COPD.
Endocrine Combinations in HR-Positive MBC: The Future Is Now
COPD Management.
Treatment Strategies in Mild to Moderate COPD
Antonio Anzueto, MD, Marc Miravitlles, MD  CHEST 
The Role of Fixed-Dose Dual Bronchodilator Therapy in Treating COPD
Advances in Managing Inhibitors in Patients With Hemophilia A
Goals of Therapy for Patients With UC
Patient Presentation. Patient Presentation PRIMO Study Incidence of Muscle Adverse Effects.
Introduction to Checkpoint Inhibitors
COPD Management.
Part 1: Disease Activity Measures
Stepping Up Asthma Control for Effective Management
The Tumor Microenvironment
The Nurse View: Best Practices in Advanced Non-Small Cell Lung Cancer
Learning Objectives. A Multidisciplinary Approach in Advanced NSCLC in the Era of Immuno-Oncology.
Dual Bronchodilation in COPD: From Clinical Trial Evidence to Clinical Practice.
Nat. Rev. Cardiol. doi: /nrcardio
What Is the Role of Dual LAMA/LABA Bronchodilation in COPD Therapy in Light of New Clinical Data?
Volume 153, Issue 4, Pages (April 2018)
Volume 153, Issue 4, Pages (April 2018)
When Would You Use Single Inhaler Triple Therapy in COPD?
Combination Inhaled Therapy in COPD: The Impact of Recent Data
Severe Asthma in Primary Care: Identification and Management
Checkpoint Inhibition
Cardiovascular Comorbidities A Common Occurrence With COPD
Therapeutic Strategies in COPD Focus on Patient Characteristics and Drug Delivery.
A Primer on Medication Delivery Systems in COPD Management
Advancing the Treatment of IBD With Biologics
Translating the Latest and Greatest Advances in PAH Into Clinical Practice.
Case #1 Case #1 (cont) Case #1 (cont)
Volume 147, Issue 4, Pages (April 2015)
Prevention of Acute Exacerbations of COPD
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Background. Advancing the Care of Patients With Moderate to Severe Atopic Dermatitis: A Case-Based Discussion.
A Primer on Medication Delivery Systems in COPD Management
Immune Checkpoint Inhibitors in Lung Cancer
Panelists. Cardiovascular Risk Modulation in Diabetes: Emerging Pathways and Insights.
Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.
Breaking News in Pemphigus Vulgaris and the Latest Updates for Your Practice.
Patient-Centered Management in Advanced Non-Small Cell Lung Cancer
Approximate Dose Equivalency of Statin LDL-C Efficacy.
Economic Burden of COPD in the Presence of Comorbidities
Clinical Challenges and Updates in Managing Seizure Clusters
The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer.
Quality Improvement and Molecular Profiling in Advanced Non-Small Cell Lung Cancer.
Prioritizing Prevention of HPV-Related Disease
New Paradigms in M0 CRPC.
Study Participant Flow
Pathogenesis of IBD, and the Role of Biologic Therapies
Volume 146, Issue 6, Pages (December 2014)
Schematic overview of the suggested pharmacological management of chronic obstructive pulmonary disease (COPD). Schematic overview of the suggested pharmacological.
Benefit–risk balance and its individual determinants with personalised chronic obstructive pulmonary disease (COPD) treatment choices. Benefit–risk balance.
Least squares (LS) mean change from baseline (95% CI) in trough forced expiratory volume in 1 s (FEV1) according to previous chronic obstructive pulmonary.
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Comparison of total β2-agonist coverage for patients prescribed a) an increased dose of extrafine inhaled corticosteroids (ICS) versus ICS+long-acting.
COPD Guidelines: A Review of the 2018 GOLD Report
Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification based on symptom and risk evaluation. a) GOLD model of symptom/risk evaluation.
Study designs for double-blind single maintenance and reliever therapy (SMART) studies. Study designs for double-blind single maintenance and reliever.
Choosing inhaler therapy for patients with stable COPD based on the Global Initiative for Chronic Obstructive Lung Disease grouping. Choosing inhaler therapy.
Presentation transcript:

Highlights From ATS 2013: An Update on Advances in COPD

Goals

Reports on the Long-Acting Muscarinic Antagonist Aclidinium

Beier et al Results

Beeh et al Report

Beeh et al Findings

Combination Inhaled Corticosteroid and LABA Therapy

Dransfield et al Findings

Abstracts From a Long-Term Safety Study of the Nebulized LABA Arformoterol

Donohue et al Findings

Donohue et al Findings (cont)

Make et al: Results of Evaluation of Lung Function

Hanania et al: Incidence of Adverse Events

Hanania et al Findings

Mahler et al Study

Mahler et al Findings

Retrospective Study Comparing Nebulized LABA With Nebulized SABA

Yeaw et al

Data on Emerging Therapies

Wedzicha et al Findingsa

Data on Emerging Therapies: Umeclidinium

Challenges and Conclusions

Challenges and Conclusions (cont)

Abbreviations

References

References (cont)

References (cont)